Abstract: Apparatus and method for dissolution testing of active substances in various dosage forms is provided. The apparatus has filtration cells equipped and configured to simulate bodily functions, operate continuously and facilitate testing various types of dosage forms including, but not limited to, tablets, capsules and those having non-disintegrating substrates.

Abstract: Apparatus and method for dissolution testing of active substances in various dosage forms is provided. The apparatus has filtration cells equipped and configured to simulate bodily functions, operate continuously and facilitate testing various types of dosage forms including, but not limited to, tablets, capsules and those having non-disintegrating substrates.

Abstract: Apparatus and method for dissolution testing of active substances in various dosage forms is provided. The apparatus has filtration cells equipped and configured to simulate bodily functions, operate continuously and facilitate testing various types of dosage forms including, but not limited to, tablets, capsules and those having non-disintegrating substrates.

Abstract: The present invention provides a dissolution test cell having a chamber and slide valve for dispensing pharmaceutical dosage forms, such as tablets, capsules, and powders, into the chamber without having to open the cell and expose the chamber and its contents to the ambient environment. The present invention also facilitates removal of a partially dissolved or non-disintegrating dosage form from the chamber and cell entirely, without exposing the interior of the cell and chamber. Dissolution test apparatus comprising at least one dissolution test cell in accordance with the invention is also provided, as well as methods for its operation to obtain Level A IVIVC dissolution results which accurately correlate with in vivo dissolution results are also provided.

Abstract: Apparatus and method for dissolution testing of active substances in various dosage forms is provided. The apparatus has filtration cells equipped and configured to simulate bodily functions, operate continuously and facilitate testing various types of dosage forms including, but not limited to, tablets, capsules and those having non-disintegrating substrates.

Abstract: The present invention provides a dissolution test cell having a chamber and slide valve for dispensing pharmaceutical dosage forms, such as tablets, capsules, and powders, into the chamber without having to open the cell and expose the chamber and its contents to the ambient environment. The present invention also facilitates removal of a partially dissolved or non-disintegrating dosage form from the chamber and cell entirely, without exposing the interior of the cell and chamber. Dissolution test apparatus comprising at least one dissolution test cell in accordance with the invention is also provided, as well as methods for its operation to obtain Level A IVIVC dissolution results which accurately correlate with in vivo dissolution results are also provided.

Abstract: The present invention provides a pharmaceutical that includes, in combination, a resinate and an aversive agent. The resinate includes an ion exchange resin and an drug. The drug is a controlled substance. In variants of the invention, both the aversive agent and the controlled substance are loaded onto the ion exchange resin; the aversive agent is loaded onto the ion exchange resin, and the controlled substance is not loaded onto the ion exchange resin; the controlled substance is loaded onto the ion exchange resin, and the aversive agent is not loaded onto the ion exchange resin; or, the controlled substance is loaded onto a first ion exchange resin, and the aversive agent is loaded onto an ion exchange resin different from the first ion exchange resin.

Abstract: Equipment and method of use for in vitro buccal dissolution testing. The invention is particularly useful for evaluating the effect of taste-masking in oral dosage forms.

Abstract: A method for removing phosphate ion from an aqueous solution containing phosphate ion using a resin loaded with a hydrous oxide of an amphoteric metal ion. The resin loaded with a hydrous oxide of an amphoteric metal ion is produced by combining a resin with at least two bed volumes of an aqueous solution containing a salt of the amphoteric metal ion, and having a metal ion concentration of at least 5%, and then treating with an aqueous alkali metal hydroxide solution.

Abstract: A method for reducing undesirable odor of an anion exchange resins by preparing a composition comprising an admixture comprising an anion exchange resin having an undesirable odor and a cation exchange resin; and converting the mixture to form the composition.

Abstract: The present invention provides a dissolution test apparatus comprising, a first chamber 2 connected in series to at least a second chamber 10, wherein the first chamber 2 is capable of transferring solid test samples to the second chamber 10 and the second chamber 10 is capable of retaining the solid test samples. Further, the apparatus includes a first reservoir 21 and at least a second reservoir 22 for continuously supplying one or more media into the first chamber 2 and the second chamber 10, respectively, the chambers having stirrers 4, 11 for mixing the solid test samples and the media together. In addition, the first chamber 2 has a sample holder 38 for introducing the test samples during the continuous supply of the media into the first chamber 2. Processors 5, 16, 20 for analyzing an effluent from the chambers are also provided.

Abstract: The present invention provides a dissolution test apparatus comprising, a first chamber 2 connected in series to at least a second chamber 10, wherein the first chamber 2 is capable of transferring solid test samples to the second chamber 10 and the second chamber 10 is capable of retaining the solid test samples. Further, the apparatus includes a first reservoir 21 and at least a second reservoir 22 for continuously supplying one or more media into the first chamber 2 and the second chamber 10, respectively, the chambers having stirrers 4, 11 for mixing the solid test samples and the media together. In addition, the second chamber 10 has a filter membrane 45 overlying a base 44 of the second chamber 10, the filter membrane 45 being supported by a filter support 46, the filter support 46 being provided between the filter membrane 45 and the base 44 of the second chamber 10 to prevent distortion of the filter membrane 45. Processors 5, 16, 20 for analyzing an effluent from the chambers are also provided.

Abstract: A dosage form comprising a resin/resinate combination is described. Said dosage form allows optimization of the release rate profile of active ingredients.

Abstract: An improved process for improving the purity of an impure material, for example for producing low color nicotine is disclosed. The process involves passing a solution of less pure material, for example nicotine, in a non-aqueous solvent, such as a fluorinated hydrocarbon, for example tetrafluoroethane, through an ion exchange resin or absorbent such that the impurity is retained on the resin, and purer material passes through. The process eliminates the need for distillation to prepare a purer material, for example to separate nicotine from colour causing compounds. Said process is non-flammable, non-ozone depleting, and has low toxicity.

Abstract: A highly productive and environmentally friendly method of loading pharmaceutically active substances onto ion exchange resins using a water miscible or water-immiscible solvent is disclosed.

Abstract: The present invention relates to a resin comprising a bio-enhancer and an optional therapeutically active ingredient or precursor thereof loaded thereon. The bio-enhancer is ionizable or non-ionizable, and the resin may be a cation exchange resin or an anion exchange resin.

Abstract: An extended release dosage form and an extended release polymeric dispenser containing polymer-clay nanocomposite are provided. The polymer-clay nanocomposite contains exfoliated clay platelets dispersed in a polymer matrix. The extended release dosage form contains active ingredient in the polymer-clay nanocomposite. The extended release polymeric dispenser contains a reservoir of an active ingredient partially or completely encapsulated by a polymer-clay nanocomposite layer. Also provided are a method of providing release of an active ingredient from the extended release dosage form and a method or providing release of an active ingredient from the extended release polymeric dispenser. The extended release dosage form and the extended release polymeric dispenser are useful for the application of pharmaceutical compounds, agricultural compounds, and perfumes.

Abstract: The present invention provides an apparatus for conducting dissolution tests. The apparatus includes two or more chambers connected in series; a supply of one or more media that can be continuously passed into the chambers; an analyzer of the effluent from the chambers for substances of interest in the test; and, a temperature controller for controlling the temperature of the medium in the chambers. The first chamber is capable of transferring solid particles to the second chamber. The second chamber is capable of retaining solid. The chambers have a means of adding test materials. The chambers have a means of mixing the sample and medium; and a means of analyzing the effluent can be carried out at multiple times during the operation of the test equipment.

Abstract: The invention provides a pharmaceutical composition that includes a non-ionizable anthlemintic drug or derivative thereof loaded onto an anion exchange resin or a cation exchange resin. The non-ionizable anthlemintic is praziquantel, a praziquantel derivative, epsiprantel, or an epsiprantel derivative. The anthlemintic can also include Droncit, a derivative of Droncit, a precursor of Droncit, Drontal, a precursor of Drontal, a derivative of Drontal, Drontal Plus, a derivative of Drontal Plus, a precursor of Drontal Plus, a formulation comprising Praziquantel and Pyrantel Pamoate, and a formulation comprising Praziquantel, Pyrantel Pamoate and/or Febantel. In another variant, the invention includes a pharmaceutical composition including a basic anthlemintic drug loaded onto an anion exchange resin, or an acidic anthlemintic drug loaded onto a cation exchange resin, and a process for manufacturing the pharmaceutical composition.

Abstract: The present invention provides a pharmaceutical that includes, in combination, a core, and a coating surrounding the core comprising a resinate of an opiate. The pharmaceutical oral dosage form is failsafe, and not subject to abuse.